



23 June 2023

The Board of Directors,
Kontafarma China Holdings Limited,
Room 12A09-12A20, 12A/F,
Sun Hung Kai Centre,
30 Harbour Road,
Wanchai, Hong Kong

Dear Sirs,

Re: Kontafarma China Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) – Major Transaction in relation to Disposal of an Indirect Non-Wholly Owned Subsidiary (the “Transaction”)

We refer to the circular of the Company dated 23 June 2023 in respect of the Transaction (the “Circular”). Capitalized terms used in this letter shall have the same meaning as those defined in the Circular.


We hereby consent and confirm that we have given and have not withdrawn our written consent to the issue of the Circular with inclusion of our letter or report and references to our name in the form and context in which they appear.

We hereby confirm that as at the Latest Practicable Date:

- (i) we did not have any shareholding in any member of the Group or any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group; and
- (ii) we did not have any direct or indirect interest in any assets which had been acquired or disposed of by or leased to any member of the Group, or were proposed to be acquired or disposed of by or leased to any member of the Group, since 31 December 2022, the date to which the latest published audited financial statements of the Group were made up.

We hereby consent to this letter and/or report being made available for public display as described in the section headed “9. DOCUMENTS ON DISPLAY” under the Appendix VI of the Circular.

Yours faithfully,
For and on behalf of
Valplus Consulting Limited


Damon S.T. Wan, CFA, FRM, MRICS,
Director

Valplus Consulting Limited 瑋鉞顧問有限公司

Unit 907, 9/F, Houston Centre, 63 Mody Road, Tsim Sha Tsui East, Kowloon, Hong Kong 香港九龍尖沙咀麼地道 63 號好時中心 9 樓 907 室
Tel 電話 : 2553 9966 / FAX 傳真 : 2553 9108 / Web 網站 : www.valplus.com.hk / EMAIL 電郵 : info@valplus.com.hk